XML 31 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Costs
 6 Months Ended
Jun. 30, 2016
Restructuring and Related Activities [Abstract]  
Restructuring Costs

12. Restructuring Costs

In June 2016, the Company halted investment in PNT2258 and the DNAi platform and closed the related Phase 2 clinical trials to further enrollment. As a result, the Company closed its research facility in Plymouth, Michigan, renegotiated and terminated certain contracts, and implemented staff reductions in the United States and Canada.

The following table summarizes restructuring activities for the six months ended June 30, 2016:

 

     Contract
Termination		      Employee
Termination		      Asset
Impairment		      Total  
     (in thousands)  

Accrual balance at December 31, 2015

    $ —         $ —         $ —         $ —     

Restructuring costs charged to research and development expense

      2,787         —           —           2,787   

Restructuring costs charged to general and administrative expense

      5         186         130         321   

Non-cash charges

      (681 )       —           (130 )       (811 ) 

Cash payments

      (18 )       (129 )       —           (147 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Accrual balance at June 30, 2016

    $ 2,093       $ 57       $ —         $ 2,150   
  

 

 

     

 

 

     

 

 

     

 

 

  

The accrual balance is expected to be fully paid in early 2017.

There were no restructuring activities during the three and six months ended June 30, 2015.